Core Article Summary - Sanara MedTech Inc has entered into an exclusive license and distribution agreement with Biomimetic Innovations Ltd (BMI) for OsStic, a synthetic injectable structural bio-adhesive bone void filler, and related technologies [1][2] - The agreement includes an initial cash investment of €4.0 million by Sanara, with an additional €4.0 million contingent upon achieving development, clinical, and regulatory milestones [1] - OsStic has received Breakthrough Device Designation from the FDA, targeting over 100,000 periarticular fractures annually in the US [1][3] Agreement Details - Sanara acquires exclusive US marketing, sales, and distribution rights for OsStic and a hardware-agnostic adjunctive internal fixation technology [2] - The initial term of the agreement is five years, with options for successive two-year renewals at Sanara's discretion [2] Product and Market Potential - OsStic is designed to enhance fracture repair by optimizing fluidic dispersion, interdigitating with bone structure, and adhering firmly to bone surfaces, offering superior structural integrity compared to traditional materials [4] - The product is expected to complement Sanara's existing surgical portfolio and is anticipated to launch in the US market by Q1 2027 [4] Strategic and Financial Implications - The partnership leverages Sanara's existing commercial infrastructure and call points, enhancing its surgical product offerings [1] - The investment aligns with Sanara's strategy to improve clinical outcomes and reduce healthcare expenditures in the surgical and wound care markets [1][6] Industry and Company Background - Biomimetic Innovations Ltd, an affiliate of PBC Biomed, specializes in medical device development and commercialization, with a track record of bringing innovative technologies to market [5] - Sanara MedTech Inc focuses on transformative technologies in surgical, chronic wound, and skincare markets, with a robust product portfolio and pipeline [6]

Core Viewpoint - Sanara MedTech Inc. has expanded its executive leadership team with the appointment of Elizabeth Taylor as Chief Financial Officer and Michael McNeil as Chief Accounting Officer and Chief Administrative Officer, effective January 15, 2025, to support the company's growth in the medical technology sector [1][2][3]. Company Overview - Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies aimed at improving clinical outcomes and reducing healthcare expenditures in the surgical, chronic wound, and skincare markets [1][6]. - The company markets and distributes a range of surgical, wound, and skincare products primarily in the North American advanced wound care and surgical tissue repair markets [6][7]. Leadership Appointments - Elizabeth Taylor brings over 25 years of financial experience, including previous roles as CFO of a medical device company and COO of multiple hedge funds, which will enhance the existing finance and accounting teams [3][4]. - Michael McNeil, now serving as Chief Accounting Officer and Chief Administrative Officer, will lead financial reporting and accounting policy, building on his previous accomplishments [3][2]. Market Position and Growth Potential - Sanara has demonstrated strong sales performance and operational progress over the past five years, positioning itself well in the market with opportunities for sustained growth [3][6]. - The company aims to penetrate its large addressable market in surgical, chronic wound, and skincare sectors, indicating a focus on expanding its market share [3][6]. Product Portfolio - Sanara's product offerings include CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft, and various advanced biologic products targeting surgical and wound care markets [6][7]. - The company is also developing innovative solutions for wound care and telemedicine services, indicating a commitment to enhancing patient outcomes while managing costs [6][7].

Core Insights - Sanara MedTech Inc. expects a net revenue increase of 45% to 48% year-over-year for Q4 2024 and a full-year increase of 32% to 33% [1][5] Financial Performance - Q4 2024 net revenue is projected to be between $25.7 million and $26.2 million, driven by strong sales of soft tissue repair products, particularly CellerateRX Surgical Activated Collagen and BIASURGE [5] - Full-year net revenue for 2024 is anticipated to be in the range of $86.0 million to $86.5 million [5] - As of December 31, 2024, the company had approximately $15.9 million in cash, $30.5 million in principal debt obligations, and $24.5 million in available borrowing capacity [5] Operational Highlights - The company achieved its thirteenth consecutive record net revenue quarter, with significant sales attributed to BIASURGE due to supply chain issues caused by Hurricane Helene [4][5] - Sanara submitted 11 provisional patent applications in 2024 related to innovations in proprietary antimicrobial technologies and hydrolyzed collagen [4][5] Leadership Changes - On October 4, 2024, Mr. Keith Myers was appointed to the Board of Directors, bringing extensive experience from his role as chairman and CEO emeritus of LHC Group [5]

Core Viewpoint - Sanara MedTech Inc. is focused on developing transformative medical technologies aimed at improving clinical outcomes and reducing healthcare costs in surgical, chronic wound, and skincare markets [3]. Group 1: Company Overview - Sanara MedTech Inc. is based in Fort Worth, Texas, and is publicly traded on Nasdaq under the ticker SMTI [1]. - The company specializes in surgical, wound, and skincare products, which are marketed and distributed primarily in North America [3]. - Key products include CellerateRX® Surgical Activated Collagen, FORTIFY TRG® Tissue Repair Graft, and various antimicrobial wound care solutions [3]. Group 2: Upcoming Events - Ron Nixon, the Chairman and CEO of Sanara, will present at the Piper Sandler 36th Annual Healthcare Conference from December 3 to 5, 2024, with his presentation scheduled for December 4 at approximately 11:50 a.m. Eastern Time [1]. - Presentation materials will be available on the company's investor relations website prior to the event, and a live audio webcast will also be accessible [2]. Group 3: Product Pipeline and Strategy - Sanara's pipeline includes innovative product candidates aimed at addressing opportunistic pathogens, wound healing, and tissue debridement [3]. - The company is committed to forming long-term strategic partnerships to enhance product outcomes while lowering overall costs [3].

Core Viewpoint - Sanara MedTech Inc. (SMTI) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Recent Performance and Outlook - For the fiscal year ending December 2024, Sanara MedTech is expected to earn -$1.42 per share, reflecting a change of -173.1% from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for Sanara MedTech has increased by 30%, indicating a positive trend in earnings expectations [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - The upgrade to Zacks Rank 2 places Sanara MedTech in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10][11].

Financial Data and Key Metrics Changes - The company generated $21.7 million in net revenue during Q3 2024, a 35% increase year-over-year, marking the 12th consecutive record revenue quarter [5][20] - Adjusted EBITDA improved to $800,000 in Q3 2024, compared to $300,000 in Q3 2023 [6] - Gross profit for Q3 2024 was $19.7 million, up $5.4 million or 38% from the prior year [21] - The company reported a net loss of $2.9 million for Q3 2024, compared to a net loss of $1.1 million in Q3 2023 [23] Business Line Data and Key Metrics Changes - The Surgical segment reported a net loss of $200,000 in Q3 2024, with a year-to-date loss of $2.9 million [7] - Surgical segment generated $2.6 million in segmented EBITDA for Q3 2024 and $5.1 million year-to-date [25] - Sales of soft tissue products increased from $13.6 million in Q3 2023 to $18.9 million in Q3 2024, while bone fusion products grew from $2.3 million to $2.8 million in the same period [13] Market Data and Key Metrics Changes - Products were sold in over 1,200 hospitals across 34 states and the District of Columbia, with contracts or approvals in more than 4,000 facilities [12] - The company has selling agreements with over 300 distributors, representing more than 2,900 potential sellers [12] Company Strategy and Development Direction - The company is focused on disrupting the $100 billion-plus non-acute wound care market through its Tissue Health Plus (THP) strategy [16] - Plans to invest in THP technology platform and related infrastructure through an expected commercial launch in mid-2025 [8] - The company is pursuing financial partners that align with its strategy, including a recent $5 million investment in ChemoMouthpiece LLC [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth and improvement in operating results, particularly in the Surgical segment [27] - The company anticipates a significant opportunity in the non-acute wound care market with the THP strategy and expects a commercial launch in mid-2025 [27] Other Important Information - The company reported a cash balance of $16.3 million at the end of the quarter [26] - R&D expenses for Q3 2024 were $1.4 million, up from $1 million in Q3 2023, with a portion allocated to the THP segment [22] Q&A Session Summary Question: Rationale for the investment in ChemoMouthpiece - The investment aligns with the company's wound and skin care strategy, addressing oral mucositis caused by chemotherapy [29][30] Question: Feedback on the pilot program with the podiatry group - The pilot program is on target, with early previews receiving positive feedback [34] Question: Operational personnel recruitment for THP - The company successfully attracted skilled personnel with execution experience, enhancing platform development efforts [35] Question: Outlook on OpEx for the remainder of the year and 2025 - The company has a clear budget and expects continued growth in adjusted EBITDA without surprises [37] Question: Update on work with Tufts regarding the 18 peptides - The technical team is progressing on solutions for radiation dermatitis, complementing the strategy with InfuSystem [39] Question: Types of partners sought for THP - The company is looking for financial and execution partners, focusing on those with experience in the provider community and supply chain [41][42] Question: Profitability expectations for THP upon launch - A ramp-up will be needed to achieve profitability in the THP segment [44] Question: Update on IP progress with Cellerate and BIASURGE - The company is making good progress on IP and is scaling BIASURGE product sales [45][46] Question: Market makers and share price concerns - Management is focused on growth and adjusted EBITDA progression, with plans to avoid highly dilutive events [52][54]

Core Insights - Sanara MedTech Inc. reported its twelfth consecutive record net revenue quarter, achieving a 35% year-over-year increase to $21.7 million for Q3 2024 [2][7] - The company experienced a net loss of $2.9 million in Q3 2024, compared to a net loss of $1.1 million in Q3 2023, primarily due to increased SG&A costs and interest expenses [3][9] - Adjusted EBITDA for Q3 2024 was $0.8 million, up from $0.3 million in Q3 2023, indicating improved operational performance [10] Financial Performance - Net revenue for Q3 2024 was $21.7 million, a 35% increase from $16.0 million in Q3 2023, driven by higher sales of soft tissue repair products and market expansion [7][8] - The company reported a gross profit of $19.7 million for Q3 2024, compared to $14.3 million in Q3 2023 [21] - Total operating expenses for Q3 2024 were $21.6 million, up from $15.2 million in Q3 2023, largely due to increased selling, general, and administrative expenses [21] Strategic Developments - Sanara has agreements with over 300 distributors and has expanded its potential seller base to over 2,900 since January 2024 [3] - The company’s products were sold in over 1,200 facilities across 34 states and the District of Columbia, with contracts or approvals in more than 4,000 hospitals as of September 30, 2024 [4] - Sanara CMP LLC invested $5 million for a 6.64% ownership in ChemoMouthpiece, LLC, aligning with its wound and skin care strategy [6] Market Position - The company continues to penetrate existing accounts while expanding into new territories, increasing the number of facilities selling its products from 600+ in Q3 2023 to 900+ in Q3 2024 [7] - Sanara's product portfolio includes advanced biologic products and surgical solutions, focusing on improving clinical outcomes and reducing healthcare costs [15][16] Leadership Changes - On October 4, 2024, Sanara appointed Mr. Keith Myers, former chairman and CEO of LHC Group, to its Board of Directors, enhancing its leadership team [5]

FORT WORTH, TX, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today announced details for the release of its results for the quarter ended September 30, 2024. Sanara will issue ...

FORT WORTH, TX, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. -- Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara" or the "Company") (NASDAQ: SMTI), a medical technology company focused on improving clinical outcomes and reducing healthcare expenditures in the surgical, chronic wound and skincare markets announced today changes to its Board of Directors ("Board"). After a long tenure of service with the predecessor company and Sanara, Mr. James "Jim" Stuckert has resigned from his position a ...

Sanara MedTech Inc. (SMTI) , along with InfuSystem Inc., recently entered into an exclusive U.S. distribution agreement with ChemoMouthpiece, LLC. Sanara will execute the terms of the agreement with the help of SI Healthcare Technologies (SI Technologies), which is a 50/50 joint venture between SMTI and InfuSystem. ChemoMouthpiece owns and manufactures a clinically validated product named Chemo Mouthpiece — an oral cryotherapy device that brings relief to oral mucositis-affected patients. This device perfec ...